传统的药物涂层支架（DES）阻碍支架内皮化的完成，使得DES更易形成晚期支架内血栓。因而，亟需开发出新型药物涂层支架，在预防再狭窄的基础上，促进内皮化完成。本项目拟构建的新型支架选用PDGFR抑制剂Sunitinib作为涂层药物，在前期的工作中，已证实Sunitinib靶向抑制血管平滑肌的作用，是理想的涂层药物。在此基础上，支架联合内皮祖细胞（EPC）捕获系统，采用VE-cad抗体特异性捕获EPC，促进内皮化的完成，构建 Sunitinib药物涂层内皮祖细胞捕获支架（Sunitinib-eluting & EPC-capture stent, SEEC）。通过家兔颈动脉支架植入模型观察SEEC支架植入后影像学、形态学和分子生物学指标，评价支架的有效性和安全性。本项目拟构建的新型支架是针对DES领域未解决的重要科学问题，具有良好的科研意义和实际应用价值。

Current commercial available drug eluting stents (DES) are criticized for the hallmarks of delayed re-endothelialization, which may cause late stent thrombosis. A new DES targeting in-stent restenosis while promoting re-endothelialization is urgently needed. In this project, Platelet derived growth factor receptor (PDGFR) inhibitor Sunitinib is selected as the eluting drug for newly fabricated stents. Sunitinib specifically inhibited the proliferation of vascular smooth muscle cells, and was demonstrated to be an ideal eluting drug in our previous study. On this basis, endothelial progenitor cells (EPC) capture system was applied in combination in order to accelerate re-endothelialization, and vascular endothelial-cadherin (VE-cad) is selected as a target surface molecule to fabricate sunitinib-eluting & EPC-capture stent (SEEC). The efficiency and safety of SEEC stents will be tested in a rabbit carotid model. Imaging examinations, morphological indexes and molecular biological levels were evaluated after stent implantation. This novel SEEC stent which may become a potential candidate for treating vascular disorders has great importance and practical application value.